Core Viewpoint - AnaptysBio, Inc. (ANAB) has experienced significant selling pressure, resulting in a 32.8% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) for ANAB is currently at 28.5, indicating that the stock may be oversold and could be poised for a rebound as selling pressure exhausts [5] - The RSI is a momentum oscillator that ranges from 0 to 100, with a reading below 30 typically signaling that a stock is oversold [2][3] Group 2: Earnings Estimates - There has been a 6.1% increase in the consensus EPS estimate for ANAB over the last 30 days, driven by a strong agreement among sell-side analysts to raise earnings estimates for the current year [5] - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [5] Group 3: Zacks Rank - ANAB holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, suggesting a potential turnaround for the stock [6]

Core Insights - AnaptysBio, Inc. reported a quarterly loss of $1.14 per share, which was better than the Zacks Consensus Estimate of a loss of $1.72, representing an earnings surprise of 33.72% [1] - The company achieved revenues of $30.02 million for the quarter ended September 2024, significantly surpassing the Zacks Consensus Estimate by 279.19%, compared to revenues of $3.32 million a year ago [2] - AnaptysBio shares have underperformed the market, losing about 6.9% since the beginning of the year, while the S&P 500 gained 19.8% [3] Financial Performance - Over the last four quarters, AnaptysBio has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$1.74 on revenues of $8.11 million, and for the current fiscal year, it is -$6.84 on revenues of $31.89 million [7] Industry Context - AnaptysBio operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 38% of over 250 Zacks industries [8] - The industry’s performance can significantly impact AnaptysBio's stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of AnaptysBio's stock price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for AnaptysBio is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Emerging Growth Company ☐ FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact name of registrant as specified in its charter) Delaware 20-3828755 (State o ...

Financial Performance - Cash and investments totaled $458.0 million as of September 30, 2024, an increase of $40.1 million from $417.9 million as of December 31, 2023[8]. - Collaboration revenue was $30.0 million for the three months ended September 30, 2024, compared to $3.3 million for the same period in 2023, representing a significant increase[9]. - Net loss was $32.9 million for the three months ended September 30, 2024, compared to a net loss of $37.3 million for the same period in 2023[12]. - Total operating expenses for Q3 2024 were $52,774,000, up from $41,050,000 in Q3 2023, reflecting an increase of 28%[18]. - Net loss for Q3 2024 was $32,851,000, an improvement from a net loss of $37,308,000 in Q3 2023, indicating a reduction of 12%[18]. - Comprehensive loss for Q3 2024 was $(31,677,000), compared to $(36,047,000) in Q3 2023, showing a decrease of 12%[18]. - Basic and diluted net loss per common share for Q3 2024 was $(1.14), compared to $(1.41) in Q3 2023[18]. Research and Development - Research and development expenses were $42.2 million for the three months ended September 30, 2024, up from $30.9 million in the same period in 2023[10]. - Research and development expenses rose to $42,212,000 in Q3 2024, compared to $30,878,000 in Q3 2023, marking an increase of 37%[18]. - ANB032 Phase 2b trial in atopic dermatitis is expected to report top-line data in December 2024, with approximately 200 patients enrolled[3]. - Rosnilimab Phase 2b trial in rheumatoid arthritis is expected to report top-line data in February 2025, with approximately 420 patients enrolled[4]. - Phase 1 trial for ANB033, an anti-CD122 antagonist, was initiated in October 2024, with Phase 1b indication expected to be disclosed in 2025[6]. Expenses - General and administrative expenses were $10.6 million for the three months ended September 30, 2024, compared to $10.2 million for the same period in 2023[11]. - Total other (expense) income, net for Q3 2024 was $(10,094,000), a decline from $424,000 in Q3 2023[18]. - Non-cash interest expense for the sale of future royalties increased to $(15,413,000) in Q3 2024 from $(4,431,000) in Q3 2023[18]. Cash and Funding - The company reiterates its cash runway through year-end 2026, supported by recent funding activities[8]. - Interest income for Q3 2024 increased to $5,324,000 from $4,854,000 in Q3 2023, representing a growth of 10%[18]. - The weighted-average number of shares outstanding for Q3 2024 was 28,893,000, up from 26,546,000 in Q3 2023[18]. Licensing and Collaboration - The company intends to out-license imsidolimab, a cytokine antagonist, in 2024[6]. - Collaboration revenue for Q3 2024 was $30,017,000, a significant increase from $3,318,000 in Q3 2023, representing a growth of 804%[18].

Core Insights - AnaptysBio, Inc. is focused on developing innovative immunology therapeutics, with key upcoming clinical data releases for its drug candidates ANB032 and rosnilimab in atopic dermatitis and rheumatoid arthritis, respectively [1][2][3][4] Clinical Development Updates - Top-line Phase 2b data for ANB032, a BTLA agonist, is expected in December 2024, with approximately 200 patients enrolled in a placebo-controlled trial [3] - Top-line Phase 2b data for rosnilimab, a PD-1 agonist, is anticipated in February 2025, following the completion of enrollment of around 420 patients [4] - A Phase 1 trial for ANB033, an anti-CD122 antagonist, has been initiated in healthy volunteers, with further indications expected in 2025 [5] Financial Performance - As of September 30, 2024, the company reported cash and investments totaling $458.0 million, an increase from $417.9 million at the end of 2023, primarily due to a $100.0 million offering and $50.0 million from royalty monetization [7] - Collaboration revenue for Q3 2024 was $30.0 million, significantly up from $3.3 million in Q3 2023, driven by a commercial milestone from Jemperli sales [7] - Research and development expenses rose to $42.2 million for Q3 2024, compared to $30.9 million in Q3 2023, reflecting increased development costs for key drug candidates [7] Pipeline Overview - The company has multiple programs in clinical development, including ANB032 for atopic dermatitis, rosnilimab for rheumatoid arthritis and ulcerative colitis, and ANB101, a BDCA2 modulator, which is set to enter Phase 1 trials in Q1 2025 [9] - AnaptysBio also has legacy cytokine antagonist programs available for out-licensing, including imsidolimab, which has completed Phase 3 trials for generalized pustular psoriasis [5][9]

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate a ...

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – Thursda ...

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.Clinical-stage biotech AnaptysBio (ANAB -1.30%) has recently been something of a standout, at least on the stock exchange. According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's share price had increased by nearly 10% week to date as of Friday before market open. Although there was little market-moving dir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact name of registrant as specified in its charter) Delaware 20-3828755 (State or other jurisdiction of incorpo ...

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update • Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist • Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist • Top-line data now anticipated in Q1 2026 for Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab • IND accepte ...